Upstream Bio (UPB) Competitors $10.94 +0.02 (+0.18%) As of 09:53 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock UPB vs. ARWR, GMTX, APLS, NAMS, TWST, RXRX, DNLI, INDV, AGIO, and BEAMShould you be buying Upstream Bio stock or one of its competitors? The main competitors of Upstream Bio include Arrowhead Pharmaceuticals (ARWR), Gemini Therapeutics (GMTX), Apellis Pharmaceuticals (APLS), NewAmsterdam Pharma (NAMS), Twist Bioscience (TWST), Recursion Pharmaceuticals (RXRX), Denali Therapeutics (DNLI), Indivior (INDV), Agios Pharmaceuticals (AGIO), and Beam Therapeutics (BEAM). These companies are all part of the "pharmaceutical products" industry. Upstream Bio vs. Its Competitors Arrowhead Pharmaceuticals Gemini Therapeutics Apellis Pharmaceuticals NewAmsterdam Pharma Twist Bioscience Recursion Pharmaceuticals Denali Therapeutics Indivior Agios Pharmaceuticals Beam Therapeutics Arrowhead Pharmaceuticals (NASDAQ:ARWR) and Upstream Bio (NASDAQ:UPB) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, analyst recommendations, profitability, valuation, media sentiment, risk, institutional ownership and earnings. Which has stronger earnings & valuation, ARWR or UPB? Upstream Bio has lower revenue, but higher earnings than Arrowhead Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioArrowhead Pharmaceuticals$3.55M728.31-$599.49M-$1.40-13.37Upstream Bio$2.37M248.30-$62.81MN/AN/A Do insiders & institutionals hold more shares of ARWR or UPB? 62.6% of Arrowhead Pharmaceuticals shares are held by institutional investors. 4.3% of Arrowhead Pharmaceuticals shares are held by insiders. Comparatively, 13.6% of Upstream Bio shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Do analysts prefer ARWR or UPB? Arrowhead Pharmaceuticals currently has a consensus price target of $43.71, suggesting a potential upside of 133.49%. Upstream Bio has a consensus price target of $56.50, suggesting a potential upside of 416.45%. Given Upstream Bio's stronger consensus rating and higher possible upside, analysts plainly believe Upstream Bio is more favorable than Arrowhead Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Arrowhead Pharmaceuticals 0 Sell rating(s) 2 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.75Upstream Bio 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is ARWR or UPB more profitable? Upstream Bio's return on equity of 0.00% beat Arrowhead Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Arrowhead PharmaceuticalsN/A -45.33% -12.49% Upstream Bio N/A N/A N/A Does the media prefer ARWR or UPB? In the previous week, Arrowhead Pharmaceuticals had 3 more articles in the media than Upstream Bio. MarketBeat recorded 4 mentions for Arrowhead Pharmaceuticals and 1 mentions for Upstream Bio. Arrowhead Pharmaceuticals' average media sentiment score of 1.63 beat Upstream Bio's score of 0.93 indicating that Arrowhead Pharmaceuticals is being referred to more favorably in the media. Company Overall Sentiment Arrowhead Pharmaceuticals Very Positive Upstream Bio Positive SummaryArrowhead Pharmaceuticals and Upstream Bio tied by winning 6 of the 12 factors compared between the two stocks. Get Upstream Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for UPB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding UPB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart UPB vs. The Competition Export to ExcelMetricUpstream BioMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$584.16M$2.91B$5.51B$9.31BDividend YieldN/A2.46%4.25%4.09%P/E RatioN/A20.3628.1819.72Price / Sales248.30290.30439.19110.06Price / CashN/A42.3835.5357.53Price / Book1.257.768.235.67Net Income-$62.81M-$55.11M$3.23B$257.51M7 Day Performance-7.60%0.19%-0.61%-0.16%1 Month Performance6.11%10.80%6.63%9.89%1 Year PerformanceN/A-0.68%27.07%15.08% Upstream Bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)UPBUpstream Bio1.7791 of 5 stars$10.94+0.2%$56.50+416.5%N/A$584.16M$2.37M0.0038ARWRArrowhead Pharmaceuticals3.7504 of 5 stars$17.27+2.6%$43.71+153.1%-38.1%$2.38B$545.21M-12.29400News CoveragePositive NewsGMTXGemini TherapeuticsN/A$54.75+3.0%N/A+14.3%$2.37BN/A-54.7530APLSApellis Pharmaceuticals4.316 of 5 stars$17.81+2.2%$39.79+123.4%-52.0%$2.24B$781.37M-9.95770Trending NewsAnalyst ForecastInsider TradeAnalyst RevisionNAMSNewAmsterdam Pharma3.5255 of 5 stars$19.65+1.0%$42.89+118.3%+8.4%$2.23B$47.14M-10.544Analyst ForecastTWSTTwist Bioscience4.2609 of 5 stars$36.15+1.6%$50.40+39.4%-37.5%$2.17B$312.97M-11.12990RXRXRecursion Pharmaceuticals1.857 of 5 stars$5.25+6.4%$7.00+33.4%-37.3%$2.13B$58.84M-2.96400DNLIDenali Therapeutics4.6842 of 5 stars$14.68+3.0%$33.71+129.7%-37.9%$2.13B$330.53M-5.49430Positive NewsINDVIndivior1.2212 of 5 stars$15.40-1.0%$17.00+10.4%+51.3%$2.12B$1.17B-49.671,051Upcoming EarningsAGIOAgios Pharmaceuticals4.3958 of 5 stars$36.00+2.2%$58.60+62.8%-16.8%$2.08B$37.04M3.20390Analyst RevisionBEAMBeam Therapeutics2.2387 of 5 stars$20.13+4.9%$48.75+142.2%-26.5%$2.02B$63.52M-4.37510 Related Companies and Tools Related Companies ARWR Alternatives GMTX Alternatives APLS Alternatives NAMS Alternatives TWST Alternatives RXRX Alternatives DNLI Alternatives INDV Alternatives AGIO Alternatives BEAM Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:UPB) was last updated on 7/17/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredThe DOJ Just Paved the Way for Account SeizuresWashington is running out of money…And guess where they'll look next? When governments go broke, they take ...Priority Gold | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTurn $1K into $50K with This DeFi GemI've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Upstream Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Upstream Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free UPB Stock Alerts